Incidence and Survival of Thyroid Cancer with Lung Metastasis

Miaochun Zhong
Zhejiang Provincial People's Hospital, Hangzhou Medical College

Xianghong He
Guangdong University of Science and Technology

Lingfei Cui
the 7th Affiliated Hospital of Sun Yat-Sen University

Kefeng Lei (leikf@mail.sysu.edu.cn)
the 7th Affiliated Hospital of Sun Yat-Sen University  https://orcid.org/0000-0002-4259-1510

---

Research

**Keywords:** Thyroid cancer, lung metastases, incidence, survival, Surveillance Epidemiology and End Results database

**DOI:** https://doi.org/10.21203/rs.3.rs-161618/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Thyroid cancer (TC) is common malignancy. Lung metastasis is one of the top metastases for TC. The incidence and survival rates of TC with lung metastasis remains unclear.

Methods: Data on TC with lung metastasis and other site-specific metastases were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The chi-square tests were employed to compare the clinicopathological characteristics among patients with different sites of metastases. Kaplan-Meier analysis and log-rank tests were used for survival analysis. A Cox proportional model was used for multivariate analyses of the patient population. Statistical significance indicated by a two-tailed P value < 0.05.

Results: A total of 77322 patients with TC and known sites of distant metastases were identified from 2010-2016. The probability of isolated lung metastasis was significantly higher than that of isolated distant metastasis to other sites among TC patients (P < 0.05). Patients with isolated lung metastases had worse overall and thyroid cancer-specific survival compared to patients with isolated bone metastases (P < 0.05). There was a slight difference in thyroid cancer-specific survival between patients with lung metastasis and patients with liver metastasis (P=0.0496), while there was no significant difference in overall survival. (P >0.05). There was no significant difference in overall survival or thyroid cancer specific survival between patients with lung metastasis and those with brain metastasis (P > 0.05). Multivariate analysis revealed that white race was associated with better outcomes in terms of both endpoints in the lung metastasis population.

Conclusions: The incidence of lung metastasis from TC was higher than that of other organ metastases. Thyroid cancer patients with isolated lung metastases have worse outcomes compared to patients with isolated bone metastases and liver metastases, whereas is similar to brain metastasis. There was the worst survival outcome on patients with multi-organ metastases.

Background

Thyroid cancer (TC) is one of the most prevalent cancers. Although TC generally has a good prognosis, a subset of patients suffer metastasis, as indicated by some studies [1, 2]. The main locations of metastasis are the lung, bone, liver, and brain [1]. As other experts have reported, the most likely location for TC metastasis may be the lung [1–3]. Information on the probability of lung metastasis compared with metastasis to other locations among TC patients and the impact of lung metastasis on survival is concerned by more and more scholars and patients and the general public. However, because the rate of distant metastasis of TC is lower than that of other cancers [3, 4], a large number of cohorts with follow-up data are needed to perform such a comparison. At present, there is no prospective randomized controlled study or even a sufficiently large sample study that may provide information on this topic. Population-based data on the incidence and prognostic value of site-specific metastases for TC are lacking. The SEER database is helpful for this topic because of its sufficiently large patient population,
relatively complete datasets and follow-up data. Therefore, the objective of this study is to review the presentation of metastatic TC patients registered within the Surveillance Epidemiology and End Results (SEER) database with a particular focus on the incidence and prognostic value of lung metastasis compared with other-site metastases.

**Methods**

This study was based on the SEER database (Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisana Cases, Nov 2018 Sub (1975–2016 varying)). We retrieved the data using SEER*Stat software Version 8.3.8. Because this study is based on a publicly available database, it was exempted from Institutional Review Board (IRB) approval.

**Data collection**

We restricted our search to the SEER database (2010–2016) because detailed information about the sites of distant metastases was not available before 2010. In this study, we included cases with the site code ICD-O-3/WHO 2008 of “thyroid”, with a primary site of “thyroid gland”, and with a behavior code ICD-O-3 of “malignant”. We excluded patients without sufficient data about survival or the site of the metastases, patients without information on the age at diagnosis, and those with a SEER cause-specific death classification of “N/A not first tumor”. The data extracted from each case included age at diagnosis, race, sex, marital status, year at diagnosis, grade, histologic type ICD-O-3, number of positive regional nodes, T stage, N stage, site of metastases, surgery of the primary and distant lymph nodes (LNs) or other metastatic sites, SEER cause-specific death classification, survival time (months) and vital status. For the sake of the current analysis, thyroid cancer-specific survival was defined as the time from diagnosis to death from TC. Due to the limitation of data composition in the SEER database in different years, T staging data were based on a combination of “derived AJCC T, 7th ed (2010–2015)” data and “derived SEER combined T” data. The cases diagnosed from 2010–2015 were based on “derived AJCC T, 7th ed (2010–2015)” data, and those diagnosed in 2016 were based on “derived SEER combined T” data. This is also applied to N stage and stage group data. Because of the lack of data on distant LN metastasis in the “mets at DX-distant LN” column, when the year of diagnosis was 2010–2015, we did not analyze information about distant LN metastasis. When we compared the survival of patients with different sites of metastases, patients without exact metastasis data were excluded.

**Statistical analysis**

We utilized the chi-square test to compare the clinicopathological characteristics of patients with different sites of metastases (liver, lung, bone, and brain). We used Kaplan-Meier analysis and log-rank testing for survival comparisons between those with isolated lung metastases, liver metastases, bone metastases and brain metastases and multiorgan metastases. We utilized a Cox proportional model to perform multivariate analyses of the patients with lung metastasis. We also employed this method to compare the survival of patients with or without surgery of the primary site and surgery of the distant LNs or other metastatic sites; these analyses were performed separately for each organ metastasis site. In
addition, we also compared isolated lung metastases with lung metastases combined with one or more additional metastatic sites (≥ 2 organs) for both endpoints with this method. Accordingly, hazard ratios with corresponding 95% confidence intervals (CIs) were generated. Statistical significance was considered if a two-tailed p value < 0.05 was achieved. All of the statistical analyses were performed using SAS 9.4.

Results

Patient characteristics

A total of 77322 patients initially diagnosed with TC from 2010–2016 with known sites of distant metastases were included in our study. Table 1 summarizes the distribution of different metastatic sites for all included patients. (Table 1 for lung metastases, Table S1 for other metastases)
Table 1
Clinical features of TC patients with or without lung metastasis.

| Variable   | Lung metastasis | Chi-square P value |
|------------|-----------------|--------------------|
|            | Yse             | No                 | Total              |
|            | (N = 998)       | (N = 76,324)       | (N = 77,322)       |
| Age        |                 |                    |                    |
| ≥ 55       | 249(24.95%)     | 50,765(66.51%)     | 51,014(65.98%)     |
| < 55       | 749(75.05%)     | 25,559(33.49%)     | 26,308(34.02%)     |
| Race       |                 |                    |                    |
| White      | 745(74.65%)     | 60,807(79.67%)     | 61,552(79.60%)     |
| Black      | 100(10.02%)     | 5413(7.09%)        | 5513(7.13%)        |
| Unknown    | 4(0.40%)        | 1308(1.71%)        | 1312(1.70%)        |
| Others     | 149(14.93%)     | 8796(11.52%)       | 8945(11.57%)       |
| Sex        |                 |                    |                    |
| Male       | 458(45.89%)     | 17,547(22.99%)     | 18,005(23.29%)     |
| Female     | 540(54.11%)     | 58,777(77.01%)     | 59,317(76.71%)     |
| Married    |                 |                    |                    |
| Married    | 4(0.40%)        | 177(0.23%)         | 181(0.23%)         |
| Unmarried  | 994(99.60%)     | 76,145(99.77%)     | 77,139(99.76%)     |
| Unknown    | 0(0.00%)        | 2(0.00%)           | 2(0.00%)           |
| Grade      |                 |                    |                    |
| GradeI     | 74(7.41%)       | 14,684(19.24%)     | 14,758(19.09%)     |
| GradeII    | 39(3.91%)       | 2748(3.60%)        | 2787(3.60%)        |
| GradeIII   | 104(10.42%)     | 754(0.99%)         | 858(1.11%)         |
| GradeIV    | 295(29.56%)     | 492(0.64%)         | 787(1.02%)         |
| Unknown    | 486(48.70%)     | 57,646(75.53%)     | 58,132(75.18%)     |
| Variable                              | Lung metastasis |                        | Chi-square P value |
|--------------------------------------|-----------------|------------------------|--------------------|
|                                      | Yse             | No                     | Total              |
|                                      | (N = 998)       | (N = 76,324)           | (N = 77,322)       |
| Histologic ICD-O-3                   |                 |                        | < 0.0001           |
| Carcinoma, undiff., NOS              | 215(21.54%)     | 327(0.43%)             | 542(0.70%)         |
| Follicular adenocarcinoma, NOS       | 99(9.92%)       | 3632(4.76%)            | 3731(4.83%)        |
| Medullary carcinoma, NOS             | 39(3.91%)       | 1186(1.55%)            | 1225(1.58%)        |
| Oxyphilic adenocarcinoma             | 28(2.81%)       | 1338(1.75%)            | 1366(1.77%)        |
| Papillary & follicular adenocarcinoma| 137(13.73%)     | 26,399(34.59%)         | 26,536(34.32%)     |
| Papillary adenocarcinoma, NOS        | 312(31.26%)     | 40,869(53.55%)         | 41,181(53.26%)     |
| Papillary carcinoma, NOS             | 10(1.00%)       | 1686(2.21%)            | 1696(2.19%)        |
| Others                               | 158(15.83%)     | 887(1.16%)             | 1045(1.35%)        |
| Stage group                          |                 |                        | < 0.0001           |
| I                                    | 0(0.00%)        | 53,510(70.11%)         | 53,510(69.20%)     |
| II                                   | 92(9.22%)       | 5540(7.26%)            | 5632(7.28%)        |
| III                                  | 0(0.00%)        | 9761(12.79%)           | 9761(12.62%)       |
| VI                                   | 896(89.78%)     | 4989(6.54%)            | 5885(7.61%)        |
| Unknown                              | 10(1.00%)       | 2524(3.31%)            | 2534(3.28%)        |
| T                                    |                 |                        | < 0.0001           |
| T0                                   | 6(0.60%)        | 107(0.14%)             | 113(0.15%)         |
| T1                                   | 47(4.71%)       | 43,527(57.03%)         | 43,574(56.35%)     |
| T2                                   | 48(4.81%)       | 12815(16.79%)          | 12,863(16.64%)     |
| T3                                   | 209(20.94%)     | 15,575(20.41%)         | 15,784(20.41%)     |
| T4                                   | 560(56.11%)     | 2420(3.17%)            | 2980(3.85%)        |
| Variable                  | Lung metastasis                  | Chi-square P value |
|--------------------------|----------------------------------|--------------------|
|                          | Yse (N = 998)                    | No (N = 76,324)    | Total (N = 77,322) |
| Tx                       |                                  |                    |                   |
| N                        |                                  |                    |                   |
| N0                       | 279(27.96%)                      | 56,099(73.50%)     | 56,378(72.91%)    |
| N1                       | 613(61.42%)                      | 18,044(23.64%)     | 18,657(24.13%)    |
| Nx                       | 106(10.62%)                      | 2181(2.86%)        | 2287(2.96%)       |
| M                        |                                  |                    |                   |
| M0                       | 0(0.00%)                         | 75,590(99.04%)     | 75,590(97.76%)    |
| M1                       | 988(99.00%)                      | 603(0.79%)         | 1591(2.06%)       |
| Mx                       | 10(1.00%)                        | 131(0.17%)         | 141(0.18%)        |
| Regional                 |                                  |                    |                   |
| Positive                 | 407(40.78%)                      | 17,729(23.23%)     | 18,136(23.46%)    |
| Negative                 | 75(7.52%)                        | 23,536(30.84%)     | 23,611(30.54%)    |
| Unknown                  | 516(51.70%)                      | 35,059(45.93%)     | 35,575(46.01%)    |
| Surgery of the primary   |                                  |                    |                   |
| Yes                      | 543(54.41%)                      | 74,221(97.24%)     | 74,764(96.69%)    |
| No                       | 454(45.49%)                      | 2067(2.71%)        | 2521(3.26%)       |
| Unknown                  | 1(0.10%)                         | 36(0.05%)          | 37(0.05%)         |
| Surgery of other Reg Dis |                                  |                    |                   |
| Yes                      | 118(11.82%)                      | 1025(1.34%)        | 1143(1.48%)       |
| No                       | 879(88.08%)                      | 75,177(98.50%)     | 76,056(98.36%)    |
| Unknown                  | 1(0.10%)                         | 122(0.16%)         | 123(0.16%)        |
A total of 998 (1.29%) patients were diagnosed with lung metastases, 514 (0.66%) patients were diagnosed with bone metastases, 152 (0.20%) patients were diagnosed with liver metastases, and 87 (0.11%) patients were diagnosed with brain metastases. A total of 1034 (1.33%) patients had single-organ metastases, while 326 patients (0.42%) had multiorgan metastases. Statistically significant correlations between different baseline characteristics of patients with different sites of metastases are shown in Table 1. Surgical resection of the primary tumor was performed in 543 (54.41%) patients, while surgical resection of the distant LN(s) or other metastatic site(s) was performed in 118 (11.82%) patients when lung metastases occurred.

**Survival outcomes**

The overall and thyroid cancer-specific survival rates were compared according to the site of metastasis (Fig. 1). Patients with isolated lung metastases had worse overall and thyroid cancer-specific survival than patients with isolated bone metastases ($P < 0.0001$). There was a slight difference in thyroid cancer-specific survival between patients with lung metastasis and those with liver metastasis ($P = 0.0496$), but there was no significant difference in overall survival (lung vs. liver metastases: $P = 0.0584$). For both endpoints, there was no significant difference between patients with lung metastasis and those with brain metastases ($P > 0.05$). Regardless of whether the patients had isolated lung metastasis, liver metastasis, bone metastasis or brain metastasis, isolated metastasis was related to better overall survival and thyroid cancer-specific survival than multiple metastases.

Hierarchical analysis revealed that there was a better outcome in patients with lung metastases if token surgery was performed either for primary or the distant site(s) ($P < 0.05$) (Fig. 2). Surgery for primary lesions in patients with bone metastasis (Figure S1) showed the same survival advantage ($P < 0.05$). There was no significant difference between the outcomes of patients with liver metastases (Figure S2) or the overall survival rates of those with brain metastases (Figure S3) with and without surgery of the distant site(s) (for the overall survival of liver metastases: surgery vs. no surgery: $P = 0.13 > 0.05$, for the thyroid cancer-specific survival of liver metastases: surgery vs. no surgery: $P = 0.26 > 0.05$, for the overall survival of brain metastases: surgery vs. no surgery: $P = 0.05$).

The comparison of the survival of patients with isolated lung metastasis and multiple-organ metastases, including lung metastasis, is shown in Fig. 3. We found that there were significant differences in the outcomes of patients with isolated lung metastasis and those with combined lung-liver metastasis and lung-brain metastasis. In contrast, the overall survival and thyroid cancer-specific survival were similar in patients with isolated lung metastasis and those with combined lung-bone metastasis. Similarly, there was no significant difference in the prognosis of combined lung-liver metastasis, lung-brain metastasis and metastasis of more than three organs, including the lung.
The multivariate analysis results shown in Table 2 revealed that white race was associated with better overall survival and thyroid cancer-specific survival in the population of patients with lung metastasis.
### Table 2
Multivariate analyses of overall survival and thyroid cancer-specific survival in TC patients with lung metastasis.

| Variable | Overall survival | Thyroid cancer-specific survival |
|----------|------------------|----------------------------------|
|          | Hazard ratio(95%CI) | p value | Hazard ratio(95%CI) | p value |
| Age      |                  |         |                    |         |
| ≤55      | 1.00(reference)  |         | 1.00(reference)  |         |
| ≥55      | 0.86(0.69 ~ 1.07) | 0.1668  | 0.94(0.77 ~ 1.16) | 0.5869  |
| Race     |                  |         |                    |         |
| White    | 1.00(reference)  |         | 1.00(reference)  |         |
| Black    | 1.47(1.06 ~ 2.04) | 0.0220  | 1.49(1.11 ~ 2.01) | 0.0087  |
| Others   | 1.28(0.95 ~ 1.71) | 0.1011  | 1.24(0.95 ~ 1.63) | 0.1097  |
| Unknown  | 9.98(3.63 ~ 27.46) | 0.0000  | 10.26(3.93 ~ 26.78) | 0.0000  |
| Gender   |                  |         |                    |         |
| Male     | 1.00(reference)  |         | 1.00(reference)  |         |
| Female   | 0.95(0.77 ~ 1.16) | 0.6077  | 0.94(0.78 ~ 1.14) | 0.5509  |
| Married  |                  |         |                    |         |
| Married  | 1.00(reference)  |         | 1.00(reference)  |         |
| Unmarried| 29.11(0.00 ~ NA) | 0.5482  | 18.60(0.02 ~ NA) | 0.4108  |
| T        |                  |         |                    |         |
| T0       | 1.00(reference)  |         | 1.00(reference)  |         |
| T1       | 1.02(0.39 ~ 2.64) | 0.9705  | 1.03(0.43 ~ 2.48) | 0.9396  |
| T2       | 1.11(0.43 ~ 2.87) | 0.8256  | 1.12(0.47 ~ 2.68) | 0.7978  |
| T3       | 0.90(0.36 ~ 2.23) | 0.8184  | 0.88(0.39 ~ 2.03) | 0.7720  |
| T4       | 0.80(0.32 ~ 1.97) | 0.6229  | 0.84(0.37 ~ 1.93) | 0.6828  |
| Tx       | 0.64(0.24 ~ 1.71) | 0.3730  | 0.67(0.28 ~ 1.61) | 0.3671  |
| N        |                  |         |                    |         |
| N0       | 1.00(reference)  |         | 1.00(reference)  |         |
| N1       | 1.13(0.89 ~ 1.43) | 0.3147  | 1.21(0.97 ~ 1.52) | 0.0849  |
| Nx       | 1.14(0.71 ~ 1.82) | 0.5795  | 1.25(0.84 ~ 1.86) | 0.2787  |
| SP       |                  |         |                    |         |
| No       | 1.00(reference)  |         | 1.00(reference)  |         |
| Yes      | 27.78(0.00 ~ NA) | 0.9128  | 17.95(0.00 ~ NA) | 0.8770  |
| Unknown  | 19.16(0.00 ~ NA) | 0.9225  | 8.75(0.00 ~ NA) | 0.9075  |
| SD       |                  |         |                    |         |
| No       | 1.00(reference)  |         | 1.00(reference)  |         |
| Yes      | 1.07(0.82 ~ 1.40) | 0.6254  | 1.12(0.86 ~ 1.44) | 0.3970  |

**Discussion**
The main findings of this study are the incidence and prognostic value of the lung metastasis of TC compared with that of other site-specific metastases. This will help us to have a better-informed discussion with the patients concerned and help us understand the overall prospect of the disease. Moreover, survival data about whether surgical treatment of the primary or distant LN(s) or other metastatic site(s) is beneficial for TC lung metastasis and other organ metastases will help us make more appropriate clinical decisions.

In our analysis, we found that white race patients had a survival advantage in terms of both overall survival and thyroid cancer-specific survival when lung metastases occurred. It may not in other study. Referring to other studies[5–7], this may be explained by better social support, including medicare. But other experts considered it as an independent prognostic factor of recurrence and metastasis in thyroid cancers[8]. This factor may be interrelated with the treatment factors of the disease. Notably, except for surgical information, other related treatment information was incomplete in the SEER database. The multivariate analysis of this study revealed that surgery, as an important part of treatment, played a significant role in the outcomes of metastatic TC, especially for lung metastasis and bone metastasis. This reveals that we should be active in the treatment of TC metastases.

In this study, we found that lung metastasis had worse outcome than bone metastasis. Bone metastasis might have a good prognosis [9, 10], but not surely in lung metastases. Some reports showed metastatic lung cancer from thyroid had better prognosis than the lung metastases from other cancer[11].

The prognostic advantage of surgery over a conservative approach for primary thyroid tumors is obvious among those with lung and other-organ metastases. However, for the treatment of metastatic sites, different strategies should be adopted for different locations of metastasis from the thyroid. Our studies have shown that patients with lung and bone metastases with a good prognosis can benefit from surgical treatment of distant LN(s) or other metastatic site(s) in terms of both overall survival and disease-specific survival. This is similar to the general strategy for other metastatic cancer with better prognosis, that is, surgery for distant lesions can improve the prognosis [12–14].

Other studies have reported a similar trend that multiple-site metastases are not associated with an increased risk of death[15]. After comparing the survival data of isolated lung metastasis with that of multiple-organ metastasis including lung metastasis, a phenomenon was revealed: the prognosis of isolated lung metastasis from TC was similar to that of lung-bone metastasis from TC; however, there was a significant difference between the prognosis of isolated lung metastasis and other multiple-organ metastasis including lung metastasis (≥ 3 organs). The cooccurrence of two metastatic lesions with a relatively good prognosis did not change the prognosis.

However, we have to consider the inherent difficulties of SEER database analysis, and the above results in particular should be cautiously interpreted. Prospective controlled studies are thus needed to evaluate the prognosis of patients, which could avoid many interference factors and allow further analysis. However, this work would take a long time to accumulate enough cases. Multicenter clinical studies or large-scale databases with more details may help us.
Conclusions

Based on the SEER analysis, the lung is the most prevalent site of metastasis from the thyroid. Similar to brain metastasis, the lung metastasis of TC had a worse outcome than liver or bone metastases. The worst survival outcome was observed in patients with multiorgan metastases. Further research is needed to identify the precise subset of patients who may benefit from local treatment of the primary tumor and/or metastatic lesions.

Declarations

Ethics approval and consent to participate

All SEER data were accessed with approval from the SEER database and, as such, this article does not contain any studies with human participants or animals performed by any of the authors.

Consent for publication

Not applicable

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

Kefeng Lei was supported by a grant from the Natural Science Foundation of Zhejiang Province of China (grant number LY18H160039). The sponsor also partially funded the journal's Rapid Service Fee.

Authors' contributions

Conceptualization: Miaochun Zhong, Kefeng Lei.

Data curation: Miaochun Zhong, Xianghong He, Lingfei Cui.

Formal analysis: Miaochun Zhong, Xianghong He, Lingfei Cui.

Funding acquisition: Kefeng Lei.

Methodology: Miaochun Zhong, Kefeng Lei.

Supervision: Kefeng Lei.
Writing – original draft: Miaochun Zhong, Kefeng Lei.

Writing – review & editing: Xianghong He, Lingfei Cui, Kefeng Lei.

Acknowledgements

This manuscript was edited for proper English language, grammar, punctuation, spelling, and overall style by some experts at American Journal Experts. This assistance was funded by the study sponsor.

References

1. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007, 110.

2. Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, Miyauchi A. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg. 2012;36:1274–8.

3. Sohn SY, Kim HI, Kim YN, Kim TH, Kim SW, Chung JH. Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up. Clin Endocrinol (Oxf). 2018;88:318–26.

4. Cho SW, Choi HS, Yeom GJ, Lim JA, Moon JH, Park DJ, Chung JK, Cho BY, Yi KH, Park YJ. Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors. Thyroid. 2014;24:277–86.

5. Chen AC, Livhits MJ, Du L, Wu JX, Kuo EJ, Yeh MW, Leung AM. Recent Pregnancy Is Not Associated with High-Risk Pathological Features of Well-Differentiated Thyroid Cancer. Thyroid. 2018;28:318–26.

6. Francis DO, Pearce EC, Ni S, Garrett CG, Pensio DF. Epidemiology of vocal fold paralyses after total thyroidectomy for well-differentiated thyroid cancer in a Medicare population. Otolaryngol Head Neck Surg. 2014;150:548–57.

7. Goldfarb M, Freyer DR. Comparison of secondary and primary thyroid cancer in adolescents and young adults. Cancer. 2014;120:1155–61.

8. Rubinstein JC, Herrick-Reynolds K, Dinauer C, Morotti R, Solomon D, Callender GG, Christison-Lagay ER. Recurrence and Complications in Pediatric and Adolescent Papillary Thyroid Cancer in a High-Volume Practice. J Surg Res. 2020;249:58–66.

9. Sakamoto T, Nio Y, Sakamoto M, Imai S, Uesugi K, Tamaoki M, Tamaoki M, Maruyama R. [Clinical Impact of First Metastasis Sites and Subtypes in the Outcome of Brain Metastases of Breast Cancer]. Gan To Kagaku Ryoho. 2020;47:1197–203.

10. Ren Y, Dai C, Zheng H, Zhou F, She Y, Jiang G, Fei K, Yang P, Xie D, Chen C. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget. 2016;7:53245–53.
11. Ronga G, Filesi M, Montesano T, Nicola AD, Vestri AR. Lung metastases from differentiated thyroid carcinoma. *The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of* 2004, 48:12–19.

12. Abdel-Rahman O. Role of liver-directed local tumor therapy in the management of hepatocellular carcinoma with extrahepatic metastases: a SEER database analysis. Expert Rev Gastroenterol Hepatol. 2017;11:183–9.

13. Shien T, Nakamura K, Shibata T, Kinoshita T, Aogi K, Fujisawa T, Masuda N, Inoue K, Fukuda H, Iwata H. A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. Jpn J Clin Oncol. 2012;42:970–3.

14. Ruiterkamp J, Voogd AC, Tjan-Heijnen VC, Bosscha K, van der Linden YM, Rutgers EJ, Boven E, van der Sangen MJ, Ernst MF. Dutch Breast Cancer Trialists G: SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation. BMC Surg. 2012;12:5.

15. Chopra S, Garg A, Ballal S, Bal CS. Lung metastases from differentiated thyroid carcinoma: prognostic factors related to remission and disease-free survival. Clin Endocrinol (Oxf). 2015;82:445–52.